MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum[1]. TG2/FN complex[1].
Pre-treatment with MT4 sensitizes ovarian cancer (OC) cells to traditional anticancer drug[1].
[1]. Sima LE, et al. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. Mol Cancer Ther. 2019 Jun;18(6):1057-1068.
















